Advertisement

GP130 in Human Myeloma/Plasmacytoma

  • Y. Tani
  • N. Nishimoto
  • A. Ogata
  • Y. Shima
  • K. Yoshizaki
  • T. Kishimoto
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 194)

Abstract

Interleukin 6 (IL-6) is a potent growth factor for human myeloma/plasmacytoma cells (Kawano et al. 1988, Klein et al. 1989) The evidences that 1) myeloma cells produce IL-6 and express IL-6 receptor (IL-6R), 2) IL-6 augments the in vitro growth of myeloma cells, 3) anti-IL-6 antibody (Ab) or anti-IL-6R Ab inhibits their growth (Klein et al. 1991, Sato et al. 1993) support the autocrine or paracrine mechanism of IL-6 for myeloma cell growth. The cytoplasmic region of IL-6R is very short (Yamasaki et al. 1988) and a signal transducing molecule, gp130 was discovered (Hibi et al. 1990). Furthermore, leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF) and IL-11 have been shown to share the same signal transducer, gp130 in their receptor systems (for review see Kishimoto et al. 1994). On the basis of this finding, it seems likely that these cytokines as well as IL-6 may be the growth factors for human myeloma/ plasmacytoma cells (Nishimoto et al. 1994, Zhang et al. 1994). In this report, we show the stimulatory effect of LIF and OSM and the inhibitory effect of anti-gp130 monoclonal antibody (mAb) on the growth of freshly isolated plasmacytoma cells.

Keywords

Multiple Myeloma Myeloma Cell Leukemia Inhibitory Factor Ciliary Neurotrophic Factor Signal Transduce Molecule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexanian R and Dimopoulos M (1994) The treatment of multiple myeloma. New Engl J Med 330: 48–489PubMedCrossRefGoogle Scholar
  2. Hibi M, Murakami M, Saito M, Hirano T, Taga T and Kishimoio T (1990) Molecular cloning and expression of an IL-6 signal transducer, gpl30. Cell 63: 1149–1157PubMedCrossRefGoogle Scholar
  3. Kishimoto T, Taga T and Akira S (1994) Cytokine signal transduction. Cell 76: 253–262PubMedCrossRefGoogle Scholar
  4. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A and Kishimoto T (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83–85PubMedCrossRefGoogle Scholar
  5. Klein B, Zhang X-G, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M and Bataille R (1989) Paracrine rather than autocrine regulation of myeloma- cell growth and differentiation by interleukin-6. Blood 73: 517–526PubMedGoogle Scholar
  6. Klein B, Wijdenes J, Zhang X-G, Jourdan M, Boiron J-M, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B, Lu Z-Y, Mannoni P, Sany J and Bataille R (1991) Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78: 1198–1204PubMedGoogle Scholar
  7. Nishimoto N, Ogata A, Shima H, Yoshizaki K and Kishimoto T(1994) Oncostatin M, leukemia inhibitory factor and interleukin-6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gpl30. J Exp Med 179: 1343–1347PubMedCrossRefGoogle Scholar
  8. Paul SR, Barut BA, Bennet F, Cochran MA and Anderson KC (1992) Lack of a role of interleukin 11 in the growth of multiple myeloma. Leuk Res 16: 247–252.PubMedCrossRefGoogle Scholar
  9. Sato K, Tsuchiya M, Saldanha J,. Koishihara Y, Ohsugi Y, Kishimoto T and Bendig MM (1993) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 53: 851–856PubMedGoogle Scholar
  10. Zhang X-G, Gu J-J, Lu Z-Y, Yasukawa K, Yancopoulos GD, Turner K, Shoyab M, Taga T, Kishimoto T, Bataille R and Klein B (1994) Ciliary neurotrophic factor, interleukin 11, leukemia inhibitory factor and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transduction. J Exp Med 179: 1337–1342PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • Y. Tani
    • 1
  • N. Nishimoto
    • 1
  • A. Ogata
    • 1
  • Y. Shima
    • 1
  • K. Yoshizaki
    • 1
  • T. Kishimoto
    • 1
  1. 1.Department of Medicine IIIOsaka University Medical SchoolSuita city, OsakaJapan

Personalised recommendations